CARsgen Therapeutics Holdings Limited will establish an advanced commercial manufacturing base for CAR T-cell products in Jinshan District, Shanghai.

In the rapidly moving field, questions remain regarding long-term safety, durability of remission, and the FDA’s approach to ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies ...

Cancer has long ranked among the leading causes of death in Taiwan, and solid tumors account for more than 90% of cancer cases worldwide—making them the most challenging frontier for CAR-T cell ...

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.

PiNACLE - H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator's choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell ...

QuantumScape Corporation is progressing steadily toward commercialization, transitioning from high-risk speculation to tangible manufacturing milestones. Click for this QS stock update.

PiNACLE - H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of ...

ADCs combine antibodies with drug payloads for targeted therapy, but complex manufacturing requires monitoring CQAs across multiple entities.

Researchers expanded millions of cancer-targeting NK cells from a single donor, improving manufacturing for future therapies.